<DOC>
	<DOCNO>NCT01757223</DOCNO>
	<brief_summary>The propose Phase I/II clinical trial use determine safety toxicity direct administration vector AdVEGF-All6A+ ischemic myocardium generate preliminary evidence regard whether direct administration AdVEGF-All6A+ ischemic myocardium induce growth collateral blood vessel improve cardiac function . This three-part , multinational/multi-center , placebo control study .</brief_summary>
	<brief_title>Administration AdVEGF-All6A+ Myocardium Individuals With Diffuse CAD Via Minimally Invasive Surgery</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Males female , age 18 90 Demonstrable reversible leave ventricular ischemia viable myocardium assess ST segment/T wave abnormality detect exercise test 99mTcsestamibi singlephoton emission compute tomography ( SPECT ) prior follow exercise test Individuals coronary artery disease ( CAD ) angina refractory medical therapy Individuals experience angina class IIIV define Canadian Cardiovascular Society Individuals coronary angiogram prior 6 month demonstrate diffuse coronary artery disease consider eligible coronary artery bypass surgery , stent , angioplasty , lack suitable target lesion Individuals must medically capable undergo open thoracotomy Individuals must neutralize antiadenovirus serotype 5 titer ≤160 ; criterion base knowledge individual high anti Ad5 neutralize antibody titer may limit efficacy Hematocrit &gt; 30 % WBC &lt; 10,000 Normal prothrombin , partial thromboplastin time ( exclude IV heparin therapy ) Normal liverrelated serum parameter Glomerular filtration rate ( GFR ) &gt; 30 ml/min No evidence active infection type , include adenovirus , hepatitis virus ( A , B C ) human immunodeficiency virus No evidence central nervous system , major psychiatric , musculoskeletal immune disorder No allergy vehicle use suspend virus contrast material use radiographic procedure Fertile infertile individual ; recommend fertile individual utilize barrier birth control measure prevent pregnancy 2 month follow administration vector Individuals receive experimental medication participate another experimental protocol least 4 week prior entry study . Individuals must able exercise least 90 second 15 min modify Bruce protocol exercise treadmill test exhibit angina concurrent 1 mm horizontal downsloping STsegment depression The study individual must able undergo procedure protocol Willingness participate study Capable providing inform consent Individuals meet inclusion criterion unable participate protocol Individuals participation study would compromise normal care expect progression disease Individuals receive corticosteroid immunosuppressive medication Individuals uncontrolled diabetes Diabetic individual significantly abnormal ophthalmologic exam ( moderate great disease severity ) Individuals hypercholesterolemia ( LDL 190 mg/dl total cholesterol 240 mg/dl ) Body mass index &gt; 35 Recent ( &lt; 6 wk ) cerebral vascular accident Recent ( &lt; 6 wk ) transmural myocardial infarction Evidence infection define elevated white blood cell count , temperature &gt; 38.5ºC , infiltrate chest xray Unable undergo cardiac MRI gadolinium contrast Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) value 2.5 great normal limit Prior cardiac transplantation Electrocardiograph abnormality would interfere STsegment analysis Untreated malignant ventricular arrhythmia Valvular heart disease require surgical intervention Preoperative congestive heart failure ( New York Heart Association Function Class III IV ejection fraction ( EF ) &lt; 25 % Uncontrollable asthma COPD Greater first degree heart block sinus node dysfunction without functional pacemaker Systolic blood pressure le 90 mmHg Known hypersensitivity adenosine Pregnancy currently lactate Prior participation cardiac gene and/or cardiac cell therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Diffuse Coronary Artery Disease ( CAD )</keyword>
</DOC>